Background: Primary central nervous system lymphoma (PCNSL) is a rare primary brain tumor. Because of its rarity and the increasing incidence rates as the U.S. population ages, it is important for nurses to understand the unique needs of patients and their caregivers during the disease continuum...

Background: Acalabrutinib is a selective Bruton tyrosine kinase inhibitor approved for patients with relapsed or refractory mantle cell lymphoma, an aggressive B-cell malignancy. Treatment-related adverse events (AEs) can have a negative effect on treatment adherence. Objectives: This article aims...

Background: Informational and supportive care resources are needed for Hodgkin lymphoma (HL) survivors. Objectives: The aim of this article is to adapt and evaluate a previously developed survivorship care website for HL survivors. Methods: A mixed-methods, user-centered design, including one-time...